The firm will pick two lead agents targeting PSMA and CLDN18.2 later this year and a third STEAP1-targeting drug next year.

If there are no dose-limiting toxicities, the company will test the CAR T-cell therapy at higher doses in more patients with FLT3-expressing refractory AML.

SNUG01 showed favorable safety and signs of early clinical efficacy in a recently completed investigator-initiated trial in China, the firm said.